Skip to main content

Table 1 Characteristics of the study population, overall and by seropositivity for anti-PT IgG

From: Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study

  Total (n = 1999) Seropositivea (n = 295) Seronegativeb (n = 1704)
Demographics
 Age (years) 47.4 ± 17.7 48.8 ± 19.4 47.1 ± 17.4
 Female 1212/1999 (60.6) 160/295 (54.2) 1052/1704 (61.7)
Pertussis-related history
 Pertussis vaccination 882/1163 (75.8) 127/165 (77.0) 755/998 (75.7)
 Prior pertussis 88/1566 (5.6) 15/227 (6.6) 73/1339 (5.5)
  Infant 3/87 (3.4) 0 3/73 (4.1)
  Child 75/87 (86.2) 13/14 (92.9) 62/73 (84.9)
  Adolescent 3/87 (3.4) 1/14 (7.1) 2/73 (2.7)
  Adult 6/87 (6.9) 0 6/73 (8.2)
 Long-lasting coughc 164/1971 (8.3) 20/290 (6.9) 144/1681 (8.6)
 Recent contact with a person with pertussis/long-lasting coughc 227/1795 (12.6) 30/270 (11.1) 197/1525 (12.9)
 Regular contact with children 919/1999 (46.0) 122/295 (41.4) 797/1704 (46.8)
 Relevant medicationsd 241/1962 (12.3) 39/287 (13.6) 202/1675 (12.1)
 Relevant hospitalizationse 10/1994 (0.5) 4/294 (1.4) 6/1700 (0.4)
  1. Data are mean ± SD or n/N (%), where N is the number of subjects with known data
  2. Abbreviations: Anti-PT IgG anti-pertussis toxin immunoglobulin G, OD optical density, SD standard deviation
  3. a>0.3 OD units
  4. b≤0.3 OD units
  5. cLasting ≥3 weeks in the previous 12 months
  6. dAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months
  7. eHospitalized due to respiratory infections in the previous 12 months